Previous Article | Next Article ![]()
Journal of Virology, May 2007, p. 4904-4908, Vol. 81, No. 9
0022-538X/07/$08.00+0 doi:10.1128/JVI.02509-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Partners AIDS Research Center, Massachusetts General Hospital,1 Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts,2 Viral Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland,3 Lemuel Shattuck Hospital, Harvard Medical School, Boston, Massachusetts,4 Centers for Disease Control and Prevention, Atlanta, Georgia,5 Department of Epidemiology and Biostatistics, University of California, San Francisco, California,6 Center for Regenerative Medicine and Technology, Massachusetts General Hospital Cancer Center, Harvard Medical School, and Harvard Stem Cell Institute, Boston, Massachusetts7
Received 14 November 2006/ Accepted 19 February 2007
The cellular immunity against Kaposi's sarcoma-associated herpesvirus (KSHV) is poorly characterized and has not been compared to T-cell responses against other human herpesviruses. Here, novel and dominant targets of KSHV-specific cellular immunity are identified and compared to T cells specific for lytic and latent antigens in a second human gammaherpesvirus, Epstein-Barr virus. The data identify a novel HLA-B57- and HLA-B58-restricted epitope in the Orf57 protein and show consistently close parallels in immune phenotypes and functional response patterns between cells targeting lytic or latent KSHV- and EBV-encoded antigens, suggesting common mechanisms in the induction of these responses.
Published ahead of print on 28 February 2007.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»